Technically there is no discrete “cut-off” for high-Hh or low-Hh expressing GBM in order to stratify patients for therapy with Hh inhibitor drugs, despite the inter-tumor differences in GLI1 expression among the patients varied in 3 orders of magnitude. This evidence concerns the gene GLI1 and neoplasm.